Preview

Rheumatology Science and Practice

Advanced search

ChTO DELAT'', ESLI V PERIOD LEChENIYa INGIBITORAMI FAKTORA NEKROZA OPUKhOLI α VOZNIK PSORIAZ?

https://doi.org/10.14412/1995-4484-2011-1466

Abstract

Ingibitory faktora nekroza opukholi α (FNO α) – infliksimab, adalimumab i etanertsept – k aprelyu 2009 g. poluchili bolee 2 mln bol'nykh vo vsem mire. Vse eti preparaty okazalis' odinakovo effektivny (okolo 60% bol'nykh otvetili na lechenie) pri revmatoidnom artrite (RA), ankiloziruyushchem spondilite (AS), psoriaze, psoriaticheskom artrite i odobreny dlya lecheniya etikh boleznei [1, 2]. Odnako ikh ispol'zovanie mozhet byt' svyazano s tselym ryadom neblagopriyatnykh reaktsii, odnoi iz kotorykh yavlyaetsya obostrenie ili razvitie novykh sluchaev psoriaza [3].

About the Authors

Yu. V. Muravyev
murawyu@mail.ru


I. A. Doroshkevich



Review

For citations:


Muravyev Yu.V., Doroshkevich I.A. ChTO DELAT'', ESLI V PERIOD LEChENIYa INGIBITORAMI FAKTORA NEKROZA OPUKhOLI α VOZNIK PSORIAZ? Rheumatology Science and Practice. 2011;49(5):89-91. (In Russ.) https://doi.org/10.14412/1995-4484-2011-1466

Views: 818


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1995-4484 (Print)
ISSN 1995-4492 (Online)